Biomerica announced that several new Gastrointestinal groups have signed up and begun using the Company’s revolutionary inFoods IBS Product. This expansion demonstrates growing recognition and adoption of the inFoods IBS test in the medical community, broadening Biomerica’s influence in providing innovative solutions for Irritable Bowel Syndrome while positioning the Company for product revenue growth over the coming quarters. These new groups join Gastro Health, a group with 390 GI physicians which was the Company’s first large physician group customer. In addition, several additional Gastro Health office locations have started using the inFoods IBS therapy for their IBS patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMRA:
- Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups
- REPEAT – Biomerica Reports First Quarter 2024 Financial Results
- Biomerica Reports First Quarter 2024 Financial Results
- Biomerica files to sell $20M of common stock
- Biomerica announces Dubai gov approved insurance reimbursement for EZ Detect